These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3963)

  • 61. [Beta adrenergic drugs in arterial hypertension].
    Gysling E
    Union Med Can; 1972 Jul; 101(7):1336-41. PubMed ID: 4402882
    [No Abstract]   [Full Text] [Related]  

  • 62. Intravenous beta-blockade in coronary heart disease: is cardioselectivity or intrinsic sympathomimetic activity hemodynamically useful?
    Taylor SH; Silke B; Lee PS
    N Engl J Med; 1982 Mar; 306(11):631-5. PubMed ID: 6120457
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension.
    Wilcox RG; Hampton JR
    Br Heart J; 1981 Nov; 46(5):498-502. PubMed ID: 6119103
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A comparison of single doses of bucindolol and oxprenolol in hypertensive patients.
    Webster J; Petrie JC; Robb OJ; Jamieson M; Verschueren J
    Br J Clin Pharmacol; 1985 Oct; 20(4):393-400. PubMed ID: 2866786
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Oxprenolol hydrochloride: pharmacology, pharmacokinetics, adverse effects and clinical efficacy.
    Russo ME; Covinsky JO
    Pharmacotherapy; 1983; 3(2 Pt 1):68-81. PubMed ID: 6344036
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effect of indomethacin on plasma renin activity and urinary aldosterone of patients with essential hypertension.
    Pedrinelli R; Arzilli F; Cavasinni L; Poli L; Sassano P; Salvetti A
    J Endocrinol Invest; 1978 Oct; 1(4):315-20. PubMed ID: 756881
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol.
    Ferrara LA; Mancini M; Marotta T; Pasanisi F; Fasano ML
    Eur J Clin Pharmacol; 1986; 29(6):717-9. PubMed ID: 3519237
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Clinical pharmacology of a new beta-adrenergic blocking agent--Trasicor].
    Votchal BE; Zamotaev IP; Lozinskiĭ LG; Sandomirskiĭ BL; Vorob'eva ZV
    Ter Arkh; 1973 Aug; 45(8):10-4. PubMed ID: 4149629
    [No Abstract]   [Full Text] [Related]  

  • 69. Renin levels and cardiovascular morbidity: a prospective study of the effect of beta-adrenergic blocking drugs.
    Hauger-Klevene JH
    Curr Med Res Opin; 1981; 7(7):443-51. PubMed ID: 6114813
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Medroxalol combined with hydrochlorothiazide in the treatment of hypertension.
    Vlachakis ND; Valasquez M; Alexander N; Maronde RF
    J Clin Pharmacol; 1983 Oct; 23(10):419-27. PubMed ID: 6139390
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
    Prichard BN
    Drugs; 1984; 28 Suppl 2():51-68. PubMed ID: 6151891
    [TBL] [Abstract][Full Text] [Related]  

  • 72. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
    Browne GA; Griffin TP; O'Shea PM; Dennedy MC
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Once daily dosage beta-blockade: antihypertensive efficacy of slow release oxprenolol as related to renin and age.
    Bühler FR; Lütold BE; Küng M; Koller FJ
    Aust N Z J Med; 1976 Aug; 6(3 Suppl):37-43. PubMed ID: 1071402
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Trasidrex (a fixed combination of slow Trasicor 16o mg and Navidrex 0.25mg) in the treatment of hypertension: a multicentre clinical trial in general practice.
    Ebbut AF; Elsdon-Dew RW; Murphy JE
    J Int Med Res; 1978; 6(6):494-8. PubMed ID: 720740
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Oxprenolol: clinical pharmacology, pharmacokinetics, and pharmacodynamics.
    Kendall MJ; John VA
    Am J Cardiol; 1983 Nov; 52(9):27D-33D. PubMed ID: 6356863
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Double-blind factorial trial.
    Chalmers J; Tiller D; Horvath J; Bune A
    Lancet; 1976 Aug; 2(7981):328-31. PubMed ID: 60566
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.
    McInnes GT; Brodie MJ
    Eur J Clin Pharmacol; 1988; 34(6):605-11. PubMed ID: 3169112
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Beta blockade in essential hypertension: an analysis of response to oxprenolol.
    Barritt DW; Marshall AJ
    Br Heart J; 1977 Aug; 39(8):825-8. PubMed ID: 901673
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluation of indoramin added to oxprenolol and bendrofluazide as a third agent in severe hypertension.
    Marshall AJ; Kettle MA; Barritt DW
    Br J Clin Pharmacol; 1980 Sep; 10(3):217-21. PubMed ID: 7437237
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy of low-dose captopril given twice daily to patients with essential hypertension uncontrolled by a beta blocker plus thiazide diuretic.
    Muiesan G; Alicandri C; Agabiti-Rosei E; Fariello R; Montini E; Muiesan ML; Boni E; Cinquegrana A; Zaninelli A
    J Int Med Res; 1984; 12(4):221-8. PubMed ID: 6381166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.